The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.
 
Michael Timothy Tees
Speakers' Bureau - Celgene; Pharmacyclics
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Calibr; Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Legend Biotech; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy; Royalty income from Takeda Pharmaceuticals
Travel, Accommodations, Expenses - Alimera Sciences; Celgene; Chugai Pharma; Kite/Gilead; Legend Biotech; Medscape; Merck; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
 
Parameswaran Hari
Honoraria - Abbvie/Pharmacyclics; Amgen; BMS; GlaxoSmithKline; Incyte; Janssen Oncology; Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics; Sanofi; Takeda
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)
 
Sham Mailankody
Honoraria - Physicans' Education Resource; Weber Shandwick
Research Funding - Alimera Sciences (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Takeda (Inst)
 
David Bernard Miklos
Consulting or Advisory Role - Adaptive Biotechnologies; Alimera Sciences; Janssen; Juno/Celgene; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics; Precision Biosciences
Research Funding - Adaptive Biotechnologies; Alimera Sciences; Kite, a Gilead company; Novartis; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics/Janssen
 
Frederick Lundry Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Celgene; Cellular Biomedicine Group; Cowen; EcoR1 Capital; GammaDelta Therapeutics; Gerson Lehrman Group; Iovance Biotherapeutics; Legend Biotech; Novartis; WUGEN, Inc.
Research Funding - Alimera Sciences (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Rajneesh Nath
Stock and Other Ownership Interests - Pfizer
Honoraria - Actinium Pharmaceuticals
Consulting or Advisory Role - Actinium Pharmaceuticals
 
Sacha Leandra Prashad
No Relationships to Disclose
 
Xiangdong Zhou
No Relationships to Disclose
 
Eren Demirhan
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
Travel, Accommodations, Expenses - Allogene Therapeutics
 
Srinand Ponnathapura Nandakumar
Employment - Alder BioPharmaceuticals; Allogene Therapeutics; Biomarin (I)
Stock and Other Ownership Interests - Alder BioPharmaceuticals; Allogene Therapeutics; Biomarin (I)
Travel, Accommodations, Expenses - Alder BioPharmaceuticals; Allogene Therapeutics; Biomarin (I)
 
Dennis Fisher
Employment - P Less Than
Leadership - P Less Than
Stock and Other Ownership Interests - United Health Group
Consulting or Advisory Role - Allakos; Allogene Therapeutics; Aqua Institute; Ayala Pharmaceuticals; Connect Biopharma; Epalex Corporation; GlycoMimetics; OPKO Biologics; Origin Biosciences; Regulus Therapeutics; Tizona Therapeutics, Inc.; Vanda Pharmaceuticals
Research Funding - Allogene Therapeutics
Patents, Royalties, Other Intellectual Property - Nuclear RNA Networks; Nuclear RNA Networks (I)
 
Gregory Opiteck
Employment - Allogene Therapeutics; Gossamer Bio
Stock and Other Ownership Interests - Allogene Therapeutics; Gossamer Bio
Consulting or Advisory Role - Gossamer Bio
Travel, Accommodations, Expenses - Allogene Therapeutics; Gossamer Bio
 
Ena Wang
Stock and Other Ownership Interests - PrimeVax